Citation
Major RW, Shepherd D, Brunskill NJ. Reclassification of chronic kidney disease stage, eligibility for cystatin-c and its associated costs in a UK primary care cohort. Nephron. 2018;139(1):39-46.
Abstract
Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) estimations of glomerular filtration rate (eGFR), compared to modification of diet in renal disease (MDRD), have superior performance in predicting renal, cardiovascular and mortality events. Cystatin-C further improves prediction. Our primary aim was to assess the change in prevalence and classification of CKD in converting from MDRD to CKD-EPI in an unselected primary care CKD population. Our secondary aims were to determine the eligibility for cystatin-C testing based on National Institute for Health and Care Excellence guidance and the associated costs.
Access publication here